Abstract: Novel drug targets and antiviral agents are provided for the therapeutic intervention of lentiviral diseases, in particular AIDS.

Abstract: A bacterial host cell is disclosed including at least two copies of an amplification unit in its genome, the amplification unit including: i) at least one copy of a gene of interest, and ii) an expressible conditionally essential gene, wherein the conditionally essential gene is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of the conditionally essential gene, and wherein the conditionally essential gene if not functional would render the cell auxotrophic for at least one specific substance or unable to utilize one or more specific sole carbon source; methods for producing a protein using the cell of the invention, and methods for constructing the cell of the invention.

Abstract: Influenza hemagglutinin (HA) binds to aluminum salt adjuvants and cannot easily be directly assayed directly a single radial immunodiffusion (SRID) test. The invention modifies the SRID protocol for an adsorbed antigen by including a step in which antigen is desorbed prior to diffusion.

Abstract: A method for dissociating avidin or streptavidin efficiently from a biotin derivative, thereby making it possible to isolate a target material efficiently under a mild condition in a short period, and a dissociation agent for use thereof, are provided. The method for dissociating avidin or streptavidin from a biotin derivative, includes mixing a combination of avidin or streptavidin with desthiobiotin with a water-soluble polymer to which biotin or a derivative thereof is bound.

Abstract: This invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a biological sample of the subject for an anti-body to a GABAB receptor. This invention further provides methods of treating an autoimmune encephalitis or an epilepsy, comprising the steps of detecting an antibody to a GABAB receptor and treating a tumor associated with the disease.

Abstract: The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.

Abstract: Compositions and methods are provided for identifying agents which have efficacy for the treatment of disorders related to aberrant cilial structure and function, including polycystic kidney disease.

Abstract: The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy.

Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.

Abstract: A reagent for classifying and counting leukocytes containing (1) a cyanine fluorescent dye; and (2) a glycoside compound; a reagent kit containing the reagent for classifying and counting leukocytes as well as its preparation process; and a process for classifying and counting blood cells using the reagent or kit are provided. Using the reagent, kit and/or process provided, leukocytes can be classified and counted in four groups with a high degree of differentiation and a better classification among each subpopulation of leukocytes, especially in that it successfully addresses the indistinct classification between lymphocytes and monocytes and between the eosinophils and neutrophils in a scattergram.

Abstract: The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed.

Abstract: A method for measuring cholesterol in low-density lipoprotein contained in a sample, which comprises reacting a sample with (i) a combination of cholesterol ester hydrolase and cholesterol oxidase or (ii) a combination of cholesterol ester hydrolase, an oxidized coenzyme and cholesterol dehydrogenase in the presence of: [a] a polyoxyethylene-polyoxyalkylene alkylaryl ether; [b] one or more surfactants selected from the group consisting of a polyoxyethylene-polyoxyalkylene copolymer, a polyoxyethylene alkenyl ether, a polyoxyethylene branched alkyl ether, and a polyoxyethylene-polyoxyalkylene branched alkyl ether; [c] one or more surfactants selected from the group consisting of a primary amine, a secondary amine, a tertiary amine, and a quaternary ammonium; and [d] a polyanion, and measuring a substance formed or consumed in the reaction.

Abstract: Novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.

Abstract: A method of enhancing an enzymatic activity of a disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13 (ADAMTS-13) by substituting on or more positions in the isolated human ADAMTS-13.

Abstract: This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.

Abstract: The invention provides a protein labeling and detection system based on self-complementing fragments of fluorescent and chromophoric proteins. The system of the invention is exemplified with various combinations of self-complementing fragments derived from Aequorea victoria Green Fluorescent Protein (GFP), which are used to detect and quantify protein solubility in multiple assay formats, both in vitro and in vivo.

Abstract: This invention relates to methods of expressing eukaryotic proteins in prokaryotic hosts, particularly eukaryotic proteins that require formation of disulfide bridges for biological activity. Various approaches are used including fusion to thioredoxin, cytoplasmic expression of disulfide isomerases, deficiencies in thioredoxin and/or glutathione reductases, deficiencies in proteases, and the like. The method is applicable to express monomeric and dimeric forms of the eukaryotic protein with biological activity such as monomeric and dimeric forms of a disintegrin or a disintegrin domain. Included are the vectors, host cells expressing the proteins, the expressed proteins and methods of using the proteins.

Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.

Abstract: Isolated chimeric proteins including up to ten copies of peptides, polypeptides or protein domains inserted in the amino termini of the Brucella spp. Lumazine synthase enzyme. Isolated nucleotide sequences codifying the chimeric proteins. Vectors, plasmids and transformed cells used for expressing the proteins. Monoclonal and polyclonal antibodies induced by the chimeric proteins. Hybridomas producing the monoclonal antibodies. Vaccines and pharmaceutical compounds including the chimeric proteins, nucleotide sequences and antibodies. A method to induce an immune response in higher organisms including the administration of effective amounts of the vaccines and pharmaceutical compounds. Biosensors including the chimeric proteins. Protein conjugates formed by the chimeric proteins and a ligand bound by means of covalent and noncovalent bonds.

Abstract: The present invention relates to a process for producing a human-type glycoprotein having reduced glycosylation by genetically manipulating an enzyme involved in glycosylation using a Hansenula polymorpha system. In detail, the present invention relates to a process for producing a human-type glycoprotein by identifying a dolichyl-phosphate-mannose dependent ?-1,3-mannosyltransferase gene from H. polymorpha, constructing a H. polymorpha mutant strain producing a glycoprotein exhibiting reduced glycosylation by disrupting the identified gene, and subjecting the mutant strain to various genetic manipulations for the synthesis of human-type glycan.

Abstract: A method of manufacturing modified lignin and the resulting non-natural modified lignin product in which a lignin-producing polymerization reaction is performed using a polymerizable monomer having the structure: wherein at least one of the polymerizable monomers is incorporated into the resulting lignin.

Abstract: The present invention provides a method for in vitro producing an indole derivative in a one-pot reaction. The method for producing a rhamnosylated indolocarbazole compound includes the steps of transforming a plasmid carrying a gene encoding N-glycosyltransferase into a bacterial strain; expressing the gene encoding N-glycosyltransferase in the bacterial strain; lysing the bacterial strain to obtain a crude enzyme extract; and adding TDP-glucose, an indolocarbazole aglycone and a metal ion in the crude enzyme extract for performing an enzymatic reaction to form the rhamnosylated indolocarbazole compound. Alternatively, the method for producing an indole-3-carboxaldehyde analog includes the steps of transforming a plasmid carrying a gene encoding NokA of Nocardiopsis sp.

Abstract: A vector of the present invention has DNA encoding a protein or a product having the same effect as the protein, the protein containing an amino acid sequence from amino acid numbers 47 to 802 in SEQ. ID. NO:2. Expression of the DNA gives human chondroitin synthase. By using human chondroitin synthase, it is possible to produce a saccharide chain having a repeating disaccharide unit of chondroitin. The DNA or part thereof may be used as a probe for hybridization for the human chondroitin synthase.

Abstract: The invention relates to the use of enzymes for copying or amplifying bisulphite modified or treated nucleic acids, wherein the enzymes are more effective in copying or amplifying the nucleic acid compared with native Taq polymerase under substantially the same conditions.

Abstract: The present invention provides compositions and improved methods for multi-site directed mutagenesis and DNA shuffling. The present compositions and methods provide increased mutation frequency and increased number of transformants which allow one to sequence only a few clones in order to identify the correct mutants and to obtain the desired mutant by screening large number of transformants in a short time. Moreover, the inclusion of FEN-1, PEF and optimized buffer and cycling conditions provided in the present invention should also facilitate random mutagenized library construction and the mutagenesis of large or difficult templates.

Abstract: The invention relates in part to methods of detecting an AAD-12 soybean event. The subject invention provides assays for detecting the presence of the subject event in a sample (of soybeans, for example). Kits and conditions useful in conducting the assays are also provided. More specifically, the present invention relates in part to an endpoint TaqMan PCR assay for the AAD-12 soybean event. Some embodiments are directed to assays that are capable of high throughput zygosity analysis. The subject invention further relates, in part, to the discovery of a preferred reference gene for use in determining zygosity. This invention also relates in part to plant breeding using any of the subject methods. In some embodiments, said event/polynucleotide sequence can be “stacked” with other traits. The subject procedures can be used to uniquely identify soybean lines comprising the event of the subject invention.

Abstract: Aspects of the present invention include methods and compositions for determining the number of individual polynucleotide molecules originating from the same genomic region of the same original sample that have been sequenced in a particular sequence analysis configuration or process. In these aspects of the invention, a degenerate base region (DBR) is attached to the starting polynucleotide molecules that are subsequently sequenced (e.g., after certain process steps are performed, e.g., amplification and/or enrichment). The number of different DBR sequences present in a sequencing run can be used to determine/estimate the number of different starting polynucleotides that have been sequenced. DBRs can be used to enhance numerous different nucleic acid sequence analysis applications, including allowing higher confidence allele call determinations in genotyping applications.

Abstract: Methods to increase the percent of polyunsaturated fatty acids (PUFAs) within the total lipids and oils of PUFA-producing oleaginous organisms are provided herein, by regulating the activity of specific acyltransferases. Specifically, since oil biosynthesis is expected to compete with polyunsaturation during oleaginy, it is possible to reduce or inactivate the activity of an organism's DAG ATs (e.g., phospholipid:diacylglycerol acyltransferase (PDAT) and/or diacylglycerol acyltransferase 1 (DGAT1) and/or diacylglycerol acyltransferase 2 (DGAT2)) to thereby reduce the overall rate of oil biosynthesis while concomitantly increasing the percent of PUFAs that are incorporated into the lipid and oil fractions. The teachings herein will thereby enable one to engineer a wide variety of oleaginous organisms to produce oils with very specific fatty acid compositions.

Abstract: The present invention is directed to improving productivity of an enzymatic method for producing esterified, transesterified or interesterified fats or oils. Specifically, a method that can greatly improve the productivity of enzymatic esterification, transesterification or interesterification by purifying the substrate oil to extend the useful life of the enzyme is disclosed.

Abstract: Acyltransferases are provided, suitable for use in the manufacture of microbial oils enriched in omega fatty acids in oleaginous yeast (e.g., Yarrowia lipolytica). Specifically, genes encoding diacylglycerol acyltransferase (DGAT1) have been isolated from Y. lipolytica and Mortierella alpina. These genes encode enzymes that participate in the terminal step in oil biosynthesis in yeast. Each is expected to play a key role in altering the quantity of polyunsaturated fatty acids produced in oils of oleaginous yeasts.

Abstract: An engineered strain of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 5.6% docosahexaenoic acid acid (DHA, an w-3 polyunsaturated fatty acid) in the total oil fraction is described. This strain comprises various chimeric genes expressing heterologous desaturases, elongases and acyltransferases and optionally comprises various native desaturase and acyltransferase knockouts to enable synthesis and high accumulation of DHA. Production host cells are claimed, as are methods for producing DHA within said host cells.

Abstract: The present invention relates to newly identified genes that encode proteins that are involved in the synthesis of L-ascorbic acid (hereinafter also referred to as Vitamin C) and/or 2-keto-L-gulonic acid (hereinafter also referred to as 2-KGA). The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechno logical tools in the production of Vitamin C and/or 2-KGA from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism.

Abstract: Disclosed is a preparation method for bio-fuel materials and bio-chemicals comprising the following steps: preparing a medium comprising fermentation waste generated in an alcohol production process; inoculating a first microorganism into the medium; and culturing the medium wherein the first microorganism was inoculated. More specifically, the preparation method for bio-fuel materials and bio-chemicals comprises the following steps: fermenting hexoses from a mixture of pentoses and hexoses to produce an ethanol fermentation broth; separating and purifying the ethanol fermentation broth; preparing a medium comprising the fermentation waste produced in the separation and purification step; inoculating a first microorganism into the medium; and culturing the medium wherein the first microorganism was inoculated.

Abstract: This invention provides processes and apparatus to convert biomass, including wood and agricultural residues, into low-ash biomass pellets for combustion, alone or in combination with another solid fuel. Some embodiments provide processes for producing hemicellulosic sugars and low-ash biomass from cellulosic biomass, comprising providing an aqueous extraction solution with acetic acid; extracting the feedstock to produce an extract liquor containing soluble ash, hemicellulosic oligomers, acetic acid, dissolved lignin, and cellulose-rich solids; dewatering and drying the cellulose-rich, lignin-rich solids to produce a low-ash biomass; hydrolyzing the hemicellulosic oligomers to produce fermentable hemicellulosic sugars, wherein additional acetic acid is generated; removing a vapor stream comprising vaporized acetic acid from the extract; recycling the vapor or its condensate to provide some starting acetic acid for the extraction solution; and recovering fermentable hemicellulosic sugars.

Abstract: In the present invention, integrated processes for producing a biofuel are disclosed. Specifically, processes integrating photobioreactors with anaerobic digestion are disclosed. Anaerobic digestion can convert biomass into a biofuel. However, anaerobic digestion also produces carbon dioxide (CO2). Because it is a greenhouse gas, the production of carbon dioxide is not desirable. Algae can be grown in a photobioreactor as long as light, carbon dioxide, and water are provided. In the present invention, the anaerobic digestion process is integrated with the photobioreactor process thereby providing a useful solution for the carbon dioxide that is generated and providing a source of carbon dioxide for the photobioreactor.

Abstract: The present invention is directed to chimeric recombinases comprising a serine recombinase operatively linked to a zinc finger nucleotide binding domain such that the chimeric recombinase protein catalyzes site-specific recombination at a DNA site specifically bound by the zinc finger nucleotide binding domain. The serine recombinase can be one of several naturally occurring serine recombinases. The invention also includes nucleic acids encoding the chimeric recombinases, vectors including the nucleic acids, host cells transformed or transfected with the vectors, methods of using the chimeric recombinases to carry out recombination, methods of using substrate-linked protein evolution to generate additional chimeric recombinases, methods of using the chimeric recombinases for gene therapy, and pharmaceutical compositions.

Abstract: The present invention relates to the isolation and characterization of a protein responsible for the reduction of uranium (VI) to uranium (IV). The present invention extends to the use of the isolated protein in the reduction of uranium (VI) to uranium (IV) and further extends to a process for the bioremediation, or at least partial remediation, of a site contaminated with a source of U (VI). According to a first aspect thereof, the present invention provides an isolated polypeptide derived from Thermus scotoductus strain SA-01 that is responsible for the reduction of uranium (VI), in a source of uranium (VI), to uranium (IV), wherein the polypeptide comprises the amino acid sequence of SEQ ID No: 1.

Abstract: Specified restriction endonucleases have been characterized for the first time by their amino acid and DNA sequences. These sequences and those with at least 90% identity thereto have been used as probes in sequence similarity analyses to identify sequence matches in a sequence database that corresponds to novel restriction endonucleases or isoschizomers. The sequence similarity analyses includes selecting a positive sequence match from any sequence producing an expectation value of less than or equal to e?02.

Abstract: The invention relates to recombinant expression of a variant form of a fungal C1 strain ?-glucosidase. The invention also relates to the generation of fermentable sugars from biomass and the production of biofuels by fermentation of the sugars using genetically modified organisms expressing the ?-glucosidase variant. The invention provides methods for producing a fermentable sugar, such as glucose, from cellobiose by contacting cellobiose with a recombinant ?-glucosidase variant protein, such as a variant protein secreted by a recombinant host cell into culture medium. Methods of the invention may be used for conversion of a biomass substrate to a fermentable sugar, and ultimately to ethanol or other biofuel.

Abstract: Disclosed is an efficient method for production of aminopeptidase. The method comprises either transforming host bacteria with an aminopeptidase gene and with a neutral protease gene, or transforming some part of host bacteria with an aminopeptidase gene while transforming the other part of the host bacteria with a neutral protease gene, culturing in a medium the hose bacteria transformed with the aminopeptidase gene and with the neutral protease gene, or culturing a mixture of the host bacteria transformed with the aminopeptidase gene and the host bacteria transformed with the neutral protease gene, to let both the aminopeptidase and the neutral protease be expressed, and collecting the aminopeptidase thus produced from the culture mixture.

Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.

Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.

Abstract: Compositions and methods comprising bacteriophages are provided. In particular, the present invention includes novel and customized T4 bacteriophages uniquely designed for effective antigen and foreign particle presentation. The present invention also provides in vitro methods for the making of customized T4 bacteriophages. The compositions and methods of the present invention may be used for effective vaccine delivery systems.

Abstract: The invention relates to a method for producing a mixture of bacteriophages, wherein at least two different bacteriophage strains have been reproduced separately, wherein a staphylococcus strain is grown in an preculture with each of strains of a bacteriophage that can lyse staphylococci and is then further reproduced in a main culture, and is then purified, and the different strains are then mixed, wherein the mixture of bacteriophages used comprises at least two different serotypes of bacteriophages that lyse specifically bacteria of the species Staphylococcus.

Abstract: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Salmonella species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Salmonella species in various settings (e.g., food safety, sanitation, probiotics).

Abstract: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Listeria species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Listeria species in various settings (e.g., food safety, sanitation, probiotics).

Abstract: A yellow pigments generation deficient Sphingomonas strain (Sphingomonas sp. ZD001) and application thereof in preparing gellan gum by microbial fermentation are provided. The strain is preserved in China Center for Type Culture Collection (CCTCC) with the address of Wuhan University, Wuhan, 430072, China, the preservation date of the strain is 10 Sep. 2009, and the preservation serial number is CCTCC No: M 209298. The main beneficial effect of the present invention is that the fermented liquor contains no yellow pigments but is milky white, colorless superior gellan gum can be obtained by only depositing polysaccharide with a small quantity of ethanol or isopropanol, so that the post purification and de-coloration techniques of gellan gum production can be simplified, the yield can be enhanced, and the production cost can be reduced.

Abstract: An oil generation system is provided. The oil generation system includes a saccharide; and a working microorganism reacting with the saccharide to produce an oil, wherein the working microorganism has a genus being a Cystofilobasidium.

Abstract: Provided is a method for enhancing the production of polyhydroxyalkanoic acid (PHA) from microorganism strains by disrupting a gene associated with the production of an exobiopolymer (EBP) in the Pseudomonas strain to redirect the carbon flux toward the production of the polyhydroxyalkanoic acid, thereby enhancing the production of the polyhydroxyalkanoic acid.

Abstract: Provided are a recombinant Ralstonia eutropha capable of producing polylactate or a hydroxyalkanoate-lactate copolymer, and a method of preparing polylactate or a hydroxyalkanoate-lactate copolymer using the same. The recombinant Ralstonia eutropha, which is prepared by introducing a gene of an enzyme converting lactate into lactyl-CoA and a gene of a polyhydroxyalkanoate (PHA) synthase using lactyl-CoA as a substrate thereto, may be cultured, thereby efficiently preparing a lactate polymer and a lactate copolymer.